Parabolic Drugs Ltd. announced unaudited standalone earnings results for the second quarter and six months ended September 30, 2016. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 141.4 million against INR 193.1 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 132.6 million against INR 753.1 million a year ago. Loss from ordinary activities before tax was INR 415.8 million against INR 1,018.6 million a year ago. Net loss for the period was INR 431.2 million against INR 1,018.6 million a year ago. Basic and diluted loss per share before and after extraordinary items were INR 6.97 against INR 16.46 a year ago. For the six months, the company reported net sales/income from operations (net of excise duty) of INR 249.8 million against INR 408.6 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 586.8 million against INR 1,264.6 million a year ago. Loss from ordinary activities before tax was INR 1,188.9 million against INR 1,787.1 million a year ago. Net loss for the period was INR 1,204.3 million against INR 1,787.1 million a year ago. Basic and diluted loss per share before and after extraordinary items were INR 19.46 against INR 28.88 year ago.